BGB-16673
BGB-16673 is an investigational new drug that is being evaluated by BeOne Medicines for the treatment of relapsed and refractory B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, and other lymphomas. BGB-16673 is a proteolysis targeting chimera that acts by harnessing the ubiquitin-proteasome system to target Bruton's tyrosine kinase for degradation.